. 2018 May;29(3):e39.

doi: 10.3802/jgo.2018.29.e39. Epub 2018 Feb 23.

Endometrial cancer risk and survival by tumor MMR status

Christina M Nagle^{1

2}, Tracy A O'Mara³, Yen Tan³, Daniel D Buchanan^{4

5

6}, Andreas Obermair^{7

8}, Penny Blomfield⁹, Michael A Quinn¹⁰, Penelope M Webb^#^{1

11}, Amanda B Spurdle^#³; Australian Endometrial Cancer Study Group

Affiliations

¹ Population Health Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia.
² School of Public Health, University of Queensland, Brisbane, Australia. christina.nagle@qimrberghofer.edu.au.
³ Genetics & Computational Biology Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia.
⁴ Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Australia.
⁵ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia.
⁶ Genetic Medicine & Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Australia.
⁷ Queensland Centre of Gynaecological Research, Royal Brisbane and Women's Hospital, Herston, Australia.
⁸ Faculty of Medicine, The University of Queensland, Brisbane, Australia.
⁹ Department of Gynaecology Oncology, Royal Hobart Hospital, Hobart, Australia.
¹⁰ Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia.
¹¹ School of Public Health, University of Queensland, Brisbane, Australia.

^# Contributed equally.

PMID: 29533022
PMCID: PMC5920223
DOI: 10.3802/jgo.2018.29.e39

Endometrial cancer risk and survival by tumor MMR status

Christina M Nagle et al. J Gynecol Oncol. 2018 May.

. 2018 May;29(3):e39.

doi: 10.3802/jgo.2018.29.e39. Epub 2018 Feb 23.

Authors

Affiliations

¹ Population Health Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia.
² School of Public Health, University of Queensland, Brisbane, Australia. christina.nagle@qimrberghofer.edu.au.
³ Genetics & Computational Biology Department, QIMR Berghofer Medical Research Institute, Royal Brisbane Hospital, Brisbane, Australia.
⁴ Colorectal Oncogenomics Group, Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Australia.
⁵ Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia.
⁶ Genetic Medicine & Family Cancer Clinic, The Royal Melbourne Hospital, Parkville, Australia.
⁷ Queensland Centre of Gynaecological Research, Royal Brisbane and Women's Hospital, Herston, Australia.
⁸ Faculty of Medicine, The University of Queensland, Brisbane, Australia.
⁹ Department of Gynaecology Oncology, Royal Hobart Hospital, Hobart, Australia.
¹⁰ Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, Australia.
¹¹ School of Public Health, University of Queensland, Brisbane, Australia.

^# Contributed equally.

PMID: 29533022
PMCID: PMC5920223
DOI: 10.3802/jgo.2018.29.e39

Abstract

Objective: The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and the risk of developing EC and survival following a diagnosis of EC.

Methods: We analyzed data from women who participated in the Australian National Endometrial Cancer Study (ANECS) conducted between 2005 and 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic and lifestyle information obtained from telephone interviews at recruitment. For survival analyses (728 cases), patients' clinical data was abstracted from medical records, and survival data were obtained via linkage with the Australian National Death Index. We used logistic regression analysis to evaluate the associations between tumor MMR status and EC risk, and proportional hazards models to perform survival analyses with adjustment of known prognostic factors.

Results: Established risk factors for EC did not differ significantly by tumor MMR status. In analyses including all EC subtypes, overall and EC-specific survival did not differ by tumor MMR status. Among women with the most common endometrioid subtype, EC-specific survival was worse for women with somatic MMR-deficient EC compared to women with MMR-proficient EC (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.19-4.01).

Conclusion: The risk of EC is not associated with MMR status. Accurate separation of germline from somatic causes of MMR deficiency suggests that patients with endometrioid subtype somatic MMR-deficient tumors have poorer EC-specific survival than those with MMR-proficient tumors, after accounting for other prognostic factors.

Keywords: DNA Mismatch Repair; Endometrial Neoplasms; Risk; Survival.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

**Fig. 1**
Association of MMR status with OS. MMR, DNA mismatch repair; OS, overall survival.

See this image and copyright information in PMC

Cited by

Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
Stinton C, Jordan M, Fraser H, Auguste P, Court R, Al-Khudairy L, Madan J, Grammatopoulos D, Taylor-Phillips S. Stinton C, et al. Health Technol Assess. 2021 Jun;25(42):1-216. doi: 10.3310/hta25420. Health Technol Assess. 2021. PMID: 34169821 Free PMC article.
An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.
Dondi G, Coluccelli S, De Leo A, Ferrari S, Gruppioni E, Bovicelli A, Godino L, Coadă CA, Morganti AG, Giordano A, Santini D, Ceccarelli C, Turchetti D, De Iaco P, Perrone AM. Dondi G, et al. Int J Mol Sci. 2020 Sep 29;21(19):7188. doi: 10.3390/ijms21197188. Int J Mol Sci. 2020. PMID: 33003368 Free PMC article.
Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
Mariya T, Kubo T, Hirohashi Y, Yanagawa J, Tabuchi Y, Matsuo K, Furumura K, Morita R, Nakatsugawa M, Kanaseki T, Tsukahara T, Hasegawa T, Saito T, Torigoe T. Mariya T, et al. Med Mol Morphol. 2021 Mar;54(1):14-22. doi: 10.1007/s00795-020-00254-6. Epub 2020 May 14. Med Mol Morphol. 2021. PMID: 32410009
Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis.
Jumaah AS, Al-Haddad HS, Salem MM, McAllister KA, Yasseen AA. Jumaah AS, et al. J Pathol Transl Med. 2021 May;55(3):202-211. doi: 10.4132/jptm.2021.02.19. Epub 2021 Apr 14. J Pathol Transl Med. 2021. PMID: 33845554 Free PMC article.
MLH1 promoter hypermethylation predicts poorer prognosis in mismatch repair deficiency endometrial carcinomas.
Kaneko E, Sato N, Sugawara T, Noto A, Takahashi K, Makino K, Terada Y. Kaneko E, et al. J Gynecol Oncol. 2021 Nov;32(6):e79. doi: 10.3802/jgo.2021.32.e79. Epub 2021 Aug 4. J Gynecol Oncol. 2021. PMID: 34431253 Free PMC article.

See all "Cited by" articles

References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. - PubMed
1. Boland CR, Koi M, Chang DK, Carethers JM. The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside. Fam Cancer. 2008;7:41–52. - PMC - PubMed
1. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783–4791. - PubMed
1. Buchanan DD, Rosty C, Clendenning M, Spurdle AB, Win AK. Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome) Appl Clin Genet. 2014;7:183–193. - PMC - PubMed
1. Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, et al. Reply to J. Moline et al. J Clin Oncol. 2014;32:2278–2279. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Endometrial cancer risk and survival by tumor MMR status

Affiliations

Endometrial cancer risk and survival by tumor MMR status

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources